Rebirth of the God-level Xueba

In Lyandell's concept, 1 million US dollars to buy 10% of the share is prepared for those drugs that have passed the first clinical phase. Tomato△Novel△Netw-w-w`. x-f`q-x`s`w. com

The first clinical phase is a safety experiment, which is prepared to test whether the drug has strong side effects.

Passing this project is not difficult. If you take a few milligrams a day, Guanyin Clay can also pass the first phase of the clinical test.

Therefore, a drug that can really get a valuation of 10 million US dollars after the first clinical phase must be well-known and promising.

Just like now, if Yang Rui or his laboratory produces a certain compound and passes the first phase of clinical trials, it will naturally be worth tens of millions of dollars.

However, Yang Rui is now empty-handed.

It is equivalent to saying that he exchanged his own name for a valuation of tens of millions of dollars.

This is $10 million in 1986, which is still quite high. Moreover, although the biomedical industry had some bubbles in the 1980s, it cannot be compared with the Internet industry after all. There are only a few pharmaceutical companies that can spend large sums of money, and they are relatively conservative.

The valuation of 15 million US dollars offered by Greenstone Corner has even washed away Lyander's perception.

It should be said that pharmaceutical companies occasionally produce one or two idiots, just like real estate developers, there will always be one who twitches his head and buys a piece of bad land with a sign, but the probability of two idiots meeting at the same time is still relatively small .

Leander looked at the manager of Greenstone Point Company on the left, and then at the manager of GlaxoSmithKline on the right, and couldn't help thinking about it.

"US$1.7 million, ten percent." Thorndike of GSK offered another price.

Hawthorne of Greenstone Corner bid $1.8 million and looked to Thorndike.

Leander is familiar with this kind of look, it is the look that if you shout again, I will withdraw.

Leander's attention fell to Thorndike's face.

Thorndike showed a smug smile, and said steadily: "1.85 million US dollars, ten percent."

He didn't need to ask for a higher price. He had to save the company a little in case Hawthorne of Greenstone Point ordered to withdraw.

Hawthorne's expression became a little distorted,

After hesitating for a few seconds, before Yang Rui was about to speak, he said, "1.5 million dollars, eight percent."

At first glance, he seems to have lowered the figure, but because the proportion required is small, the actual valuation is actually higher, reaching 18.75 million US dollars, although it is only 25% more than GlenSmithKline where Thorndike is located. The valuation of 10,000 US dollars, on the contrary, made the latter even more entangled.

Liandel suddenly realized that what the two companies were fighting for was actually the right to participate.

A 10% or 8% equity is just a barrier to entry for them. What a company really spends is only more than a million dollars.

Even by the standards of 1986, more than one million US dollars is not a huge figure for a pharmaceutical company. Whether it is for marketing or research investment, it is less than a month's expenditure.

However, Liandel did not obtain the relevant authorization from the company, which made him a little anxious.

Fortunately, Yang Rui quickly stopped Greenstone Corner and GlaxoSmithKline from cyclically asking prices, waved his hands, and said, "One thing you may not be clear about is that the new drug I made will be put into production in China."

"Huh? Made in China?" Thorndike sat up straight.

Hawthorne and Leander also showed concerned expressions. However, compared to GSK, Greenstone Corner and Calize Pharmaceuticals are small and medium-sized enterprises, and they do not have such high requirements for the source of medicines.

Not Glaxo. They are world-class multinational companies, and there are still some differences in sales of drugs produced in the United States or in China.

Of course, it is not completely impossible. For example, India has produced various drugs for European and American pharmaceutical companies for a long time, and its chemical industry was once quite prosperous.

Regardless of what the companies think, Yang Rui smiled and said: "I have two suggestions, one is to build a joint venture factory, and everyone will share the interests of the production part. If you don't want to, you can also sell as an agent, but this priority It is lower than the partner of the joint venture factory, and it will be handed over to other companies only if the joint venture party gives up sales."

Several white people looked at each other again.

"Professor Yang, Gaucher disease is a rare disease, and there are only hundreds of thousands of patients in the world. If a joint venture factory is established, the profit in production will be very low." Hawthorn and the white male who came together After a few seconds, I asked again.

"No." Yang Rui said: "We have a new idea on the enzyme replacement method. If it can be realized, it will require a larger factory to accommodate it. Therefore, the production cost and production profit will be higher than ordinary drugs. .”

"Isn't it using extracts from human placenta?" The white male behind Hawthorne suddenly asked.

"No." Yang Rui replied simply. As a rare disease, Gaucher disease has been studied in the medical field, which is one of the reasons why Yang Rui chose it. If there is no more than 20 years of research by predecessors, you have to do basic research yourself. This is not an easy job, especially the requirements of modern medicine, must be quantitative results, and give a plan or direction for granted. , are difficult to be recognized, and quantification often means long-term experiments, which is not easy.

In the initial research of Gaucher disease, the enzyme replacement method is the most natural way of thinking.

The structure of glucocerebrosidase in patients with Gaucher disease has changed, and it cannot play its due role, so it is better to supplement some normal glucocerebrosidase.

If the lacking enzyme is a common species, this solution can be regarded as a preliminary solution to Gaucher's disease. Unfortunately, the medical experts who studied Gaucher's disease in the early stage were not able to find an easy supply source of glucocerebrosidase.

In fact, most of the compounds synthesized by the human body are difficult to have a stable supply, such as the insulin needed by diabetics. After many generations of research, there is a cheap, stable and large supply.

Since there is no ready-made supply of glucocerebrosidase, it can only be searched from the human body, and finally only the human placenta is a very reluctant source of supply. A lot of trouble, after all, is something that can save lives.

However, it is conceivable that when this extraction method is used, the cost of glucocerebrosidase is extremely high, and there are very few Gaucher patients who can be treated.

Yang Rui's alternative plan is to prepare glucocerebrosidase analogues in Chinese hamster ovary cells through dna recombination technology. Although it cannot completely cure Gaucher's disease, the regimen once every two weeks can greatly Prolong the life of patients and reduce pain.

For the hundreds of thousands of people with Gaucher disease, and for the Gaucher disease patients with related gene mutations that will continue to appear in the future, this is the sound of heaven.

"Is there any other way to extract the placenta other than human placenta? Is there an experimental plan?" the people from GlaxoSmithKline continued to ask.

Yang Rui smiled, and he refused to talk about DNA recombination technology, and he didn't need to explain the drug development plan to representatives of several pharmaceutical companies, but his confidence and the halo of the Nobel Prize shrouded the entire laboratory .

"In principle, we are willing to participate in a joint venture." It was still the people from GSK who spoke first.

"We have to think about it." Hawthorne's voice was a little low. Greenstone Corner had never thought of a joint venture before.

Leander hesitated for a moment, and could only regretfully say: "We quit."

Kalizi has only sales and production departments, and relies on purchasing various formulas to make a living. They do not have the ability and ambition of multinational joint ventures.

However, Yang Rui expressed his satisfaction. From his point of view, as long as he can persuade a foreign company, it means that the plan is effective, and then he can make a plan based on it. As for how to realize it, it is the work of Secretary Hu and his office. Son.

What Yang Rui really cares about is the technology of dna recombination. Although in ten or twenty years, the recombinant DNA will be played badly by various laboratories, but the recombinant DNA is still very high-end before the Human Genome Project is completed or even actually carried out.

It is a good thing for both fame and wealth for the ion channel laboratory to be able to realize and advance it into practice.

...